The Indian government has initiated a significant move to bolster the quality assurance and safety of medicines distributed through its affordable Jan Aushadhi Kendras. This push comes via two new institutional collaborations aimed at expanding drug testing and advancing pharmaceutical research.
Boosting Quality Assurance for Generic Drugs
The Indian Pharmacopoeia Commission (IPC), operating under the Ministry of Health and Family Welfare, has signed a Memorandum of Understanding (MoU) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI). This partnership specifically targets enhancing the quality framework for medicines supplied via Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs), which are known for providing low-cost generic drugs across the nation.
Under this agreement, PMBI gains the authority to submit randomly selected batches of medicines from Jan Aushadhi outlets to the IPC for independent quality testing. This introduces an additional layer of scrutiny to ensure the efficacy and safety of these affordable medications. Both agencies will also collaborate to promote the adoption of the National Formulary of India across these centers, encouraging more rational and standardized prescribing and dispensing practices.
Furthermore, the collaboration aims to strengthen pharmacovigilance activities. This includes expanding adverse drug reaction (ADR) reporting mechanisms by displaying the Pharmacovigilance Programme of India (PvPI) QR code and helpline at Jan Aushadhi centers. Training and awareness programs for pharmacists and other stakeholders will also be conducted, focusing on rational drug use, pharmacovigilance, and overall patient safety.
Advancing Research in Biologics and Emerging Therapies
In a separate but equally important initiative, the IPC has also partnered with the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur. This second MoU is designed to strengthen research and standard-setting within pharmaceutical sciences, with a particular emphasis on biologics and other emerging therapies.
The collaboration will facilitate joint research programs focused on impurity profiling, including the investigation of genotoxic impurities like nitrosamines. A key objective is also to develop robust analytical methods, quality control protocols, and reference standards for complex biologics, biosimilars, and novel treatments such as cell and gene therapies, for eventual inclusion in the Indian Pharmacopoeia.
Beyond research, the partnership between IPC and NIPER Hajipur will foster academic exchange, provide training programs, and enable shared access to advanced analytical infrastructure. It will also support internships and fellowships, nurturing future talent in pharmaceutical research and development.
These strategic alliances underscore the government's commitment to ensuring high standards for all medicines, particularly those made accessible to a wider population through the Jan Aushadhi scheme, thereby enhancing patient safety and public trust in the pharmaceutical sector.